N-(4-bromobenzyl)-N-tosylglycine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-bromobenzyl)-N-tosylglycine
• 英文别名: 2-[(4-bromophenyl)methyl-(4-methylphenyl)sulfonylamino]acetic acid
• 化学式: C₁₆H₁₆BrNO₄S
• 分子量: 398.277
• InChiKey: SYTXTZQJEWJFFA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  83.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(4-bromobenzyl)-N-tosylglycine 在 氯化亚砜 作用下， 生成 N-(4-bromobenzyl)-N-tosylglycinoyl chloride
  参考文献：
  名称：

  [EN] METHODS FOR TREATING NEUROLOGICAL DISORDERS
  [FR] MÉTHODES DE TRAITEMENT DE TROUBLES NEUROLOGIQUES

  摘要：

  This disclosure provides compounds and pharmaceutically acceptable salts thereof, that inhibit Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) DYRK1A activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., a neurological disorder) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.

  公开号：

  WO2023107714A2
• 作为产物：
  描述：

  ethyl N-(4-bromobenzyl)-N-tosylglycinate 在 lithium hydroxide monohydrate 、 水 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 N-(4-bromobenzyl)-N-tosylglycine
  参考文献：
  名称：

  [EN] METHODS FOR TREATING NEUROLOGICAL DISORDERS
  [FR] MÉTHODES DE TRAITEMENT DE TROUBLES NEUROLOGIQUES

  摘要：

  This disclosure provides compounds and pharmaceutically acceptable salts thereof, that inhibit Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) DYRK1A activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., a neurological disorder) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.

  公开号：

  WO2023107714A2

文献信息

• [EN] METHODS FOR TREATING NEUROLOGICAL DISORDERS<br/>[FR] MÉTHODES DE TRAITEMENT DE TROUBLES NEUROLOGIQUES
  申请人：[en]PROTHENA BIOSCIENCES LIMITED

  公开号：WO2023107714A2

  公开（公告）日：2023-06-15

  This disclosure provides compounds and pharmaceutically acceptable salts thereof, that inhibit Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) DYRK1A activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., a neurological disorder) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.